Sanofi And GSK Launch Final Testing Phase Of New Covid Vaccine

The companies hope to launch their vaccine by the end of 2021 -- one year after Pfizer and Moderna jabs were approved by regulators.

French pharmaceutical giant Sanofi and Britain's GSK announced Thursday the start of final tests of their belated Covid vaccine as they race to add their jab to the world's arsenal against the pandemic. The companies reported positive results from interim human trials earlier this month after a disappointing outcome from initial studies last year left France without its own vaccine, denting national pride. Sanofi and GlaxoSmithKline on Thursday started enrolment for Phase 3 of a clinical study that will include more than 35,000 adult volunteers at sites in the United States, Asia, Africa and Latin America, the firms said. The companies hope to launch their vaccine by the end of 2021 -- one year after Pfizer and Moderna jabs were approved by regulators.